The FDA on January 23, 2020 granted accelerated approval to TAZVERIK® for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma, not eligible for complete resection. TAZVERIK® is a product of Epizyme, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
